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Rasvamaksa on yleisin pitkäaikainen maksasairaus, johon liittyy rasvapisaroiden kertyminen 
maksan soluihin. Tutkimuksessamme oletimme, että maksan rasvoittuminen näkyy myös 
muutoksina verestä mitatuissa aineenvaihduntareiteissä. 
 
Tutkittavilta henkilöiltä otettiin laskimoverinäytteet, joista selvitettiin kaikkien ihmisen geenien 
ilmentymistasot. Yksittäisistä geeneistä muodostuu aineenvaihduntareittejä, kun useat samaan 
toiminnallisuuteen liittyvät geenit yhdistetään ryhmäksi. Maksan rasvoittuminen tutkittiin 
ultraäänikuvantamisella. Tutkimus tehtiin yhteensä 1650 henkilölle, joista 316:lla oli rasvamaksa. 
 
Tuloksina saatiin 14 aineenvaihduntareittiä, jotka olivat aktiviisempia henkilöillä, joilla oli 
rasvamaksa. Reitit liittyvät soluväliaineen pilkkomiseen, immuunivasteen säätelyyn, veren 
hyytymisen tehostumiseen ja hermokudoksiin. Kun tutkimuksessa vakioitiin rasvamaksaan liittyvät 
tunnetut riskitekijät ja veriarvot, edelleen neljä reittiä oli aktivoitunut merkitsevästi (p<0,05) 
rasvamaksa-ryhmällä: i) integriini A4B1 viestitys, ii) leukosyyttien siirtyminen verisuonten 
seinämien läpi, iii) CD40/CD40L viestinvälitys ja iv) netrin-1 viestinvälitysreitti. Näistä kaikki 
paitsi ii) pysyivät aktivoituneina myös henkilöillä, joilla rasvamaksaan ei liittynyt korkeaa alkoholin 
käyttöä. 
 
Yhteenvetona tutkimuksesta, rasvamaksaan liittyi soluväliaineen pilkkomista, tulehdusvastetta, 
immuunivastetta ja veren hyytymistä lisäävien aineenvaihduntareittien aktivoituminen. Nämä 
tekijät ovat myös sydän- ja verisuonitautien taustalla ja voivat liittyä näiden molempien tautitilojen 
kehittymiseen. 
 
 
 
Tämän opinnäytteen alkuperäisyys on tarkastettu Turnitin OriginalityCheck-ohjelmalla 
Tampereen yliopiston laatujärjestelmän mukaisesti. 
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1 ABSTRACT 
Fatty liver (FL) disease is the most common type of chronic liver disease. We hypothesized that 
liver’s response to the process where large droplets of triglyceride fat accumulate in liver cells is 
reflected also in gene pathway expression in blood. 
Peripheral blood genome wide gene expression analysis and ultrasonic imaging of liver were 
performed for 1,650 participants (316 individuals with FL and 1,334 controls) of the Young Finns 
Study. Gene set enrichment analysis (GSEA) was performed for the expression data. 
Fourteen gene sets were upregulated (false discovery rate, FDR <0.05) in subjects with FL. These 
pathways related to extracellular matrix (ECM) turnover, immune response regulation, prothrombotic 
state and neural tissues. After adjustment for known risk factors and biomarkers of FL, we found i) 
integrin A4B1 signaling, ii) leukocyte transendothelial migration, iii) CD40/CD40L and iv) netrin-1 
signaling pathways to be upregulated in individuals with FL (nominal p<0.05). From these all but not 
ii) remained significantly upregulated when analyzing only subjects without history of heavy alcohol 
use. 
In conclusion, FL was associated with blood gene sets of ECM turnover, inflammatory response, 
immune system activation and prothrombotic state. These may form a systemic link between FL and 
the development of cardiovascular diseases. 
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2 INTRODUCTION 
The fatty liver disease (FLD) is a common liver disorder in western industrialized countries and an 
emerging problem in the Asia-Pacific region. FLD is often associated excessive alcohol consumption 
(alcoholic fatty liver disease, AFLD) or obesity with or without insulin resistance i.e., non-alcoholic 
fatty liver disease (NAFLD) 1, 2. Currently NAFLD is the most common cause of chronic liver disease 
3, affecting up to one third of US population 4 and 70-90% of the obese and diabetics 5. The main 
characteristic of FLD irrespective of the cause is the accumulation of triglyceride lipid droplets (>5% 
of liver weight) in liver cells 1-3, 6. The increased level of intrahepatic fatty acids may lead into cell 
damage and inflammation and provide a source of oxidative stress promoting fatty liver progression 
from steatosis to steatohepatitis and subsequently to cirrhosis or ultimately to hepatocellular 
carcinoma 2, 6. 
The primary causes leading to hepatocellular lipid accumulation are not yet well understood, but they 
are thought to include alterations in the hepatic lipid uptake, synthesis, degradation and secretion 7. 
Also, its metabolic, systemic and clinical consequences are still incompletely understood 6, 8. For 
example, clinically patients who eventually develop progressive liver cirrhosis or liver failure cannot 
be differentiated from those who do not. Immune system activation and inflammation are key players 
in the pathogenesis of FLD 9-12. NAFLD is considered as an early mediator of systemic disease 13. 
Innate immune system is deeply involved in pathophysiological events of fatty liver by following 
mechanisms: TLR-4 dependent signaling activates the Kupffer cells, complement pathway activation, 
balancing the cytokine network towards pro-inflammatory mediators, alternation in natural killer 
(NK) and NK T cell number and activity, and activation of the adaptive immune system leading to 
severe liver disease 9. The involvement of adaptive immunity in the evolution of fatty liver and its 
complications is under research. Present evidence suggests that adaptive immunity contributes not 
only to the maintenance of fatty liver but also to the progression and comorbidities of it 9, 14. Immuno-
inflammatory mechanisms are present in several comorbidities related with FLD, including obesity, 
type 2 diabetes, chronic kidney disease, metabolic syndrome, and cardiovascular diseases 5, 13. 
However, the actual pathophysiological mechanisms connecting these states are not well known.  
The purpose of the present study was to reveal alterations in gene pathways related to FLD in a 
population based study cohort. We hypothesized that accumulated fatty acids and large droplets of 
triglycerides in liver cells trigger an inflammatory response in liver, which is visible via differential 
immuno-inflammatory gene pathway expression in blood. Understanding the pathogenic mechanisms 
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of FLD and its metabolic and systemic consequences will give us new insight to the disease process 
and comorbidities of FLD. 
3 MATERIAL AND METHODS 
3.1 Subjects 
The Cardiovascular Risk in Young Finns Study (YFS) is a Finnish longitudinal population study on 
the evolution of cardiovascular risk factors from childhood to adulthood. These subjects for the 
baseline study in 1980 were randomly selected from Finnish national registry from six different age 
groups between 3 to 18 years and five different study districts 15. In the present study, we used the 
data from the follow-up in 2011, when 2,063 subjects participated in blood sampling and in clinical 
examinations. Participants in the follow-up studies have been found to be more often women and 
older than those who dropped out, but no significant differences in risk factors have been found 7, 15. 
The present study has been approved by the Ethics Committee of the Hospital District of Southwest 
Finland on September 21st, 2010. The study protocol of each study phase corresponded to the 
proposal by the World Health Organization. All subjects gave written informed consent and the study 
was conducted in accordance with the Helsinki declaration. 
3.2 Clinical examinations 
Waist and hip circumference, height and weight were measured and body mass index (BMI) 
calculated as kg/m². Blood pressure was measured as the average of three measurements taken at 2-
minute intervals in a sitting position from the right arm brachial artery by random zero 
sphygmomanometer. The metabolic syndrome was defined according to the harmonized definition 
16. 
Data regarding daily alcohol consumption, physical activity, and smoking were obtained by 
questionnaires in 2011. Alcohol consumption data were acquired by standardized questionnaires and 
calculated in standard doses (12 g pure ethanol) per day by dividing the total number of doses 
consumed per week (0.33 L doses of beer or cider, 0.12 L doses of wine, and 0.04 L doses of hard 
liquor) by 7. 17 Physical activity index was calculated (range 5-15) 18. The participants were classified 
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as smokers if they smoked daily. Subjects were classified as diabetics based on questionnaires, blood 
fasting glucose and glycated hemoglobin measurements and national medication registry records. 
Complete information on history of HIV and hepatitis C were obtained from the Finnish National 
Hospital Discharge Register. None of the participants had a diagnosis of hepatitis C or HIV, which 
could potentially have contributed to the diagnosis of fatty liver. 19 
3.3 Ultrasound imaging of liver 
Ultrasound imaging of the liver was performed for 2,040 study participants using a validated protocol 
20 and Sequoia 512 ultrasound mainframes (Acuson, Mountain View, CA, USA) with 4.0 MHz adult 
abdominal transducers. Evaluation of hepatic steatosis was performed according to liver-to-kidney 
contrast, parenchymal brightness, deep beam attenuation, and bright vessel walls 21. According to 
these criteria the presence of hepatic steatosis was assessed visually from images by a highly trained 
ultrasonographer. 22 The participants were classified into fatty liver (FL) and normal liver (NL) 
groups. 
3.4 Blood samples and biochemistry 
Venous blood samples were drawn from the right antecubital vein after an overnight fast and 
anticoagulated with EDTA. For liver enzyme quantification serum was separated, aliquoted, and 
stored at -70°C until analysis. Serum alanine aminotransferase (ALT), aspartate aminotransferase 
(AST), gamma-glutamyltransferase (GT) and triglyceride concentrations were measured by 
enzymatic methods (ALT, AST, GT and Triglycerides System Reagent, Beckman Coulter 
Biomedical, Ireland). Apolipoprotein B (ApoB) and C-reactive protein (CRP) were determined 
immunoturbidimetrically (ApoB assay reagent, Orion Diagnostica, Finland and CRP Latex reagent, 
Beckman Coulter Biomedical). The serum triglyceride concentration was assayed using the 
enzymatic glycerol kinase–glycerol phosphate oxidase method (Triglyceride reagent, Beckman 
Coulter Biomedical). 7 All the above-mentioned assays were performed on an automatic analyzer 
(AU400, Olympus, Japan).  
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3.5 RNA isolation and quality control 
Whole blood (2.5 ml) was collected into PaXgene Blood RNA Tubes (PreAnalytix). The tubes were 
inverted 8–10 times then stored at room temperature for at least 2 hours. The tubes were frozen (-
80°C) and thawed overnight before RNA isolation (both miRNA and total RNA) with a PAXgene 
Blood microRNA Kit (Qiagen) including the DNase Set using the QiaCube (Qiagen). The 
concentrations and purity of the RNA samples were evaluated spectrophotometrically (BioPhotomer, 
Eppendorf). The RNA isolation process was validated by analyzing the integrity of several RNAs 
(n=26) with the RNA 6000 Nano Chip Kit (Agilent). 7 
3.6 Genome wide expression analysis 
2,049 individuals gave blood samples to RNA isolation in the 30-year follow-up in 2011-2012. 63 
samples were discarded during the RNA isolation protocol, leading to 1,987 samples including 1 
technical replicate taking part in the genome wide expression analysis. 322 samples had too low 
concentration after amplification step. Finally, 1,667 samples were run with the expression BeadChip 
including 3 technical replicates (2 from the mRNA amplification step).  
The expression levels were analyzed with an Illumina HumanHT-12 version 4 Expression BeadChip 
(Illumina Inc.). In brief, 300–500 ng of RNA was reverse transcribed into cDNA and biotin-UTP 
labelled using the Illumina TotalPrep RNA Amplification Kit (Ambion), and 1,500 ng of cDNA was 
then hybridized to the Illumina HumanHT-12 v4 Expression BeadChip. The BeadChips were scanned 
with the Illumina iScan system. 23 
3.7 Processing of GWE microarray data 
Raw Illumina summary probe-level data was exported from Beadstudio and analyzed in R 
(http://www.r-project.org/) using the Bioconductor (http://www.bioconductor.org/) packages.  The 
HT-12 v4 BeadChip contains 47,231 expression and 770 control probes. The transcripts detected 
(detection p-value <0.01) in less than 5% of samples were excluded from the analysis. After this 
filtering 19,637 genes were used for analysis. We disregarded 4 samples with less than 6,000 
significantly detected expression probes (detection p-value <0.01). The expression data was 
processed using nonparametric background correction, followed by quantile normalization with 
control and expression probes, and log2 transformation using the neqc function in the limma package. 
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Based on RPS4Y1-2 and XIST mRNA levels on the Y and X chromosomes, respectively, we excluded 
9 samples due to mismatch with the recorded sex. After quality control, expression data were 
available for 1,654 samples including 4 technical replicates, which were used to examine batch effects 
and excluded subsequently. 1,650 non-related samples were used for further analysis. 23 
3.8 Definition of the cases and controls and statistical analysis for the 
demographics of the study population 
Subjects were classified into two groups: FL (n=316) and NL (n=1,334) by a highly trained 
ultrasonographer and FL cases were considered as alcoholic fatty liver (AFL) (n=55) if the daily 
alcohol consumption exceeded 20 g for women and 30 g for men 24. If the alcohol consumption was 
lower than these thresholds, they were classified into non-alcoholic fatty liver (NAFL) group (n=223). 
Demographics of the study participants were analyzed with R (version 3.2.2). These include all the 
parameters shown to be connected with fatty liver in a previous study of YFS participants including 
age, sex, BMI, alcohol consumption, smoking, systolic and diastolic blood pressure, waist to hip ratio, 
ApoB, triglycerides, insulin, liver enzymes (ALT, AST, GT) and physical activity index 17. Data are 
presented as mean (SD). P values <0.05 were considered significant. FL, NAFL and AFL groups 
were separately compared to control group using Mann-Whitney test for continuous parameters and 
χ2 test for classified parameters. 
3.9 Gene set enrichment analysis (GSEA) of GWE data 
The Canonical Pathways (CP) from the curated gene sets collection (C2) of the molecular signature 
database (MSigDB v5.0) database 25 were used in gene set enrichment analysis (GSEA). Only 
pathways with 15 to 500 genes were included, resulting in using altogether 870 pathways in the 
analysis. The alternative probes representing the same gene in the beadchip were collapsed to single 
genes by GSEA software, resulting in 14403 genes in the analysis. 
GSEA software 26, 27 was used to analyze the association of gene pathways with the phenotype. A 
false discovery rate (FDR) q-value < 0.25 can be considered as a significant according to the criteria 
recommended by Subramanian et al. 26. However, we used a more stringent FDR q-value < 0.05 to 
select the statistically significant pathways. GSEA performs 1000 permutations when calculating the 
FDR values. Therefore, in the result tables we present p<0.001 instead of 0 when the calculated FDR 
value appears as 0 in the GSEA results. R language (version 3.2.2) was used for adjusting the gene 
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expression data before the analysis with GSEA software. The expression levels were adjusted for sex 
and age (Model 1) and with those independent confounding factors previously associated with FL in 
our study sample (fully adjusted Model 2) 17: adjusting the gene expression for age, sex, BMI, alcohol 
consumption, ApoB, triglycerides, insulin, systolic blood pressure, ALT, and physical activity index. 
In addition, to reduce the effect of technical factors 28 we adjusted the expression levels for the first 
20 principal components as described elsewhere 23. Finally, inverse normal transformation was 
applied to the probes’ residual variance before analyzing them with the GSEA algorithm. 
Similar analysis setup using the MSigDB canonical pathways were performed for all measurements: 
FL vs. NL, NAFL vs. NL and AFL vs. NL. In addition, GSEA was performed for NAFL vs. AFL to 
reveal the differences in gene expression pathways between these states. 
3.10 Data Availability 
The datasets analysed during the current study are not publicly available due to the regulations of 
Finnish law and the ethical permissions that prohibits uploading the YFS data to public platforms. 
4 RESULTS 
4.1 General characteristics of the study sample 
General demographics of the study population is presented in Table 1. Individuals with FL were more 
often men and older and were metabolically less healthy. They also had higher BMI and waist to hip 
ratio when compared to the NL group. 1.3 % of the NL group had diabetes but for FL group the 
prevalence of diabetes was ten-fold (13.1 %). Elevated systolic and diastolic blood pressure, ApoB, 
triglycerides, insulin, increased levels of liver enzymes (ALT, AST, GT) and CRP were also 
associated with FL. In addition, alcohol consumption and decreased physical activity were 
significantly related to FL. All the mentioned characteristics differed significantly (P<0.001) between 
the groups. Only exception to the previously identified risk factors 17 was that daily smoking did not 
vary from the NL in the FL or NAFL groups in our study. However, smoking differed significantly 
(p=0.022) between the subjects with AFL and NL. In addition, in the NAFL subgroup alcohol 
consumption was similar to the NL group. The subjects in the present study are relatively young and 
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include only 11 individuals with cardiovascular diseases including heart failure, coronary artery 
disease, coronary artery bypass grafting, coronary angioplasty, cerebrovascular disease and stroke. 
However, the number of subjects with cardiovascular diseases is insufficient to provide significant 
pathway enrichment results for this group. 
4.2 Gene set enrichment analysis for FL 
Fourteen gene sets were upregulated (FDR<0.05) in subjects with FL (Table 2) in Model 1 (adjusting 
with sex, age, 20 principal components). These gene sets can be grouped into four groups describing 
the origin of the pathways: (1) pathways related to the extracellular matrix (ECM) turnover, (2) 
pathways regulating immuno-inflammatory response, (3) pathways contributing to thrombosis and 
(4) pathways related to neural tissues. 
Pathways related to the extracellular matrix (ECM) turnover include two different integrin pathways 
(integrin A4B1 and integrin cell surface interactions), ECM receptor interaction and mCalpain 
pathway. All these gene sets share several integrin genes that mediate cell adhesion to ECM.  
CD40/CD40L signaling pathway related to immune response was strongly enriched. Also, leukocyte 
transendothelial migration gene set associated to increased inflammation procedures in individuals 
with FL. Releated to these inflammation mechanisms, a pathway containing genes involved in 
signaling to extracellular signal-regulated kinases (ERKs) was also upregulated in FL group. Another 
upregulated pathway was HIVNEF, which promotes inflammation by helping CD4 helper T cells to 
prevent apoptosis. 
Three upregulated pathways increase the probability for thrombosis in FL. They include integrin 
alphaIIB beta3 signaling, platelet aggregation plug formation and urokinase plasminogen activator 
(UPA) – UPA receptor (UPAR) pathway. 
Interestingly, some of the upregulated pathways we identified in FL individuals have originally been 
identified from neural tissues. Netrin-1 signaling pathway, was initially linked to axon development 
and was recently also associated with atherosclerosis, controlling the trafficking of monocytes 
between blood and plaque 29. Another upregulated gene set was Agrin in postsynaptic differentiation 
(AGR) pathway, which is related to neuromuscular junctions and organization of cytoskeleton in 
skeletal muscle. Alpha-synuclein signaling pathway, is previously identified from presynaptic 
neurons in human brain. 
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With fully adjusted Model 2, four gene sets remained significant (nominal p<0.05) in FL group 
(Table 3). One of them was related with ECM turnover (integrin A4B1 signaling), two gene sets were 
related with immune response regulation (CD40/CD40L signaling pathway, leukocyte 
transendothelial migration) and one gene set associated with neuroimmune guidance cue 1 (netrin-1) 
signaling. 
We also present the results of FL vs. NL comparisons for Model 1 in Supplementary Table 1 and 
for Model 2 in Supplementary Table 2 with cutoff value FDR<0.25. 
4.3 Gene set enrichment analysis with fully adjusted model for NAFL and AFL 
All the 14 gene sets upregulated in FL group with Model 1 were also significantly upregulated in 
NAFL group in comparison to controls (nominal p<0.05), using Model 1 adjustments. With Model 2 
adjusting, we identified three upregulated gene sets: integrin A4B1 signaling, CD40/CD40L signaling 
pathway and netrin-1 signaling (Table 3). 
However, the corresponding results for AFL in Model 1 analysis indicated five of the defined gene 
sets were significantly enriched for upregulation. They consist of integrin cell surface interactions, 
HIVNEF pathway and all three thrombosis related pathways (integrin alphaIIB beta3 signaling, 
platelet aggregation plug formation and UPA–UPAR pathway). For Model 2 analysis with AFL, none 
of the defined 14 gene sets was significantly upregulated. 
When we compared the results of fully adjusted Model 2 with the Model 1, only a few gene sets 
remained statistically significantly upregulated for FL or NAFL. For example, all pathways related 
to thrombosis could be explained by the confounding factors. Three pathways were upregulated also 
in Model 2 analysis of FL and NAFL: integrin A4B1 signaling, CD40/CD40L signaling pathway and 
netrin-1 signaling pathway. 
5 DISCUSSION 
This large study with 1,650 participants is to our knowledge the first wide-scale peripheral blood 
based GSEA analysis of subjects with FL. We hypothesized that hepatocellular accumulation of fatty 
acids and triglycerides trigger an inflammatory response in liver, which is visible via differential 
immuno-inflammatory gene pathway expression in blood. Furthermore, we investigated the effect of 
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alcohol consumption history and fully adjusted model with previously known independent 
confounding factors to the observed gene pathways. After adjusting for the known confounding 
factors, we identified four activated pathways associated with FL, including integrin A4B1 signaling, 
leukocyte transendothelial migration (TEM), CD40/CD40L and netrin-1 signaling pathways. 
These pathways are related to the following biological leukocyte functions: (a) their adherence to 
vessel wall, (b) transmigration, and/or (c) retaining in tissues. CD40/CD40L signaling pathway is 
suggested to increase adherence of CD40 positive cells, such as platelets and monocytes, to the vessel 
wall 30. Integrin A4B1 (also known as very late antigen-4, VLA-4) signaling pathway is thought to 
be activated by chemotactic agents from injured cells 31. Together integrin A4B1 (VLA-4) and 
leukocyte TEM pathways regulate the leukocyte migration from blood to organs through endothelium 
32, 33. Netrin-1 signaling pathway increase leukocyte sensitivity to anti-inflammatory netrin-1, which 
is shown to decrease the accumulation of neutrophils but is downregulated in injured hepatic tissue 
34. As a consequence of these mechanisms, leukocytes increasingly transmigrate from blood and 
retain in injured liver tissue. Accumulated lymphocytes are known to induce fatty liver in different 
ways, such as by activating pro-inflammatory cytokines 9. Furthermore, activated inflammatory 
mechanisms increase accumulation of lipids into liver, which then induce or exacerbate the 
progression of fatty liver. In mouse model of NASH, inflammatory cells also regulate hepatic lipase 
and lipoprotein lipase: CD8+ T cells, NKT cells and cytokines secreted by them induce liver damage, 
ultimately advancing towards hepatocellular carcinoma 35. Our present findings would propose 
background mechanisms behind these previously known pathological changes in FL. 
In the present study, upregulated CD40/CD40L signaling pathway was associated with FL, especially 
NAFL. Sookoian et al. found that circulating levels of soluble CD40 ligand (sCD40L) was 
significantly higher in 113 NAFLD patients when compared to 102 control subjects 36. This result is 
in line with our present findings. Previous results by Ercin et al. controversially indicated that sCD40L 
levels did not differ between 50 NAFLD subjects and 30 healthy controls 37. However, that evaluation 
was performed with smaller number of subjects than the previous and the present study. CD40L 
deficiency has been investigated in rodent models as well. Interestingly, Poggi et al. found that both 
the genetic CD40L deficiency and neutralizing anti-CD40L antibody therapy attenuated the 
development of FL and other metabolic disorders in mice 38. Based on these previous studies and the 
present results we would suggest that C40/CD40L signaling pathway plays an important role in 
metabolic disorders such as FL. More specifically, CD40/CD40L signaling is suggested to increase 
adherence of CD40 positive cells, such as platelets and monocytes, to the vessel wall modulating 
atherothrombosis 30. 
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Integrin A4B1 signaling pathway was significantly enriched in FL and NAFL groups. As previously 
indicated, integrin A4B1 (VLA-4) is normally expressed on leukocyte plasma membranes. Activation 
of this antigen requires chemotactic agents from the site of injury i.e., endothelium or other cells. 
Endothelium expresses vascular cell adhesion molecule-1 (VCAM-1) which binds to the VLA-4 and 
enables the transmission of leukocytes from blood to organs. 31 A4B1 has also been shown to bind 
osteopontin, while facilitating hepatic neutrophil infiltration and liver injury in the rat alcoholic 
steatohepatitis model 39. Another significantly enriched pathway after adjusting for confounding 
factors was leukocyte transendothelial migration (TEM). That pathway is close to the VLA-4 pathway 
since they both regulate the migration of leukocytes from blood to tissue through endothelium 32, 33. 
These gene sets correspond to the similar biological functionality but the TEM pathway reflects more 
biological functions by 75 genes (leukocyte – endothelium cell interactions) while integrin A4B1 
signaling targets only 25 genes (leukocyte internal signaling). While Banerjee et al. associated 
leukocyte TEM functions with rat alcoholic steatohepatitis model 39, we observed that the TEM 
pathways were activated in NAFL group. However, these pathways may reflect common pathogenic 
inflammatory mechanisms behind both AFLD and NAFLD 9, 10, and it is possible that the number of 
subjects with AFL (n=55) is insufficient to reveal this change in the present study. To determine if 
there exists difference in TEM pathways between NAFL and AFL in humans, further research is 
recommended with more subjects in the AFL group. To conclude, in the present study fatty liver is 
reflected to blood gene pathways in such way where specific factors (adherence and transmigration) 
driving leukocytes to tissues are activated. 
Neuroimmune guidance cue netrin-1 signaling pathway was upregulated in FL. Initially, netrins were 
considered as cell and axon guidance cue proteins in embryogenesis, and later identified outside the 
nervous system influencing tissue morphogenesis 40. Interestingly, in the present study netrin-1 gene 
was not differentially expressed in our groups. Corresponding results have earlier been observed in 
another study, where expression of netrin-1 associated with atherosclerotic plaques, but did not differ 
in blood of patients with coronary artery disease compared with healthy controls 29. Activated netrin-
1 signaling pathway could indicate increased sensitivity of leukocytes and macrophages to the 
inflammatory mediators such as netrin-1. A recent study with mice suggests netrin-1 as an anti-
inflammatory factor in liver ischemia/reperfusion injury 34, whereas our results extend that also into 
blood of patients with fatty liver. Netrin-1 is suggested to retain macrophages in atherosclerotic 
plaques 29, and by the present results, we would suggest the corresponding effect in patients with FL.  
To conclude, these pathways strongly suggest activation of immunological and inflammatory 
processes in blood of patients with fatty liver. A blood cascade including three different steps was 
identified with association of fatty liver. Firstly, adherence and transmigration of leukocytes from 
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blood to tissues such as liver and vessel wall is activated. Secondly, interaction of monocytes and 
platelets is promoted which increases prothrombotic state. Thirdly, netrin-1 signaling pathway 
induces anti-inflammatory mechanisms by retaining leukocytes into tissues. However, in the present 
study setting we cannot determine the causality, whether the FL participates in production of these 
inflammatory factors into blood or do the dysregulated gene pathways refer to systemic disturbances 
from which FL is one result. Therefore, we are unable to evaluate whether the activation of 
inflammation system in liver or blood is more important for FL. At least, our results may reflect 
common metabolic and inflammatory disturbances behind atherosclerosis and FL. Corresponding 
metabolic results have been identified in a study by Wree et al., where increased adipocyte size 
associated with elevated liver enzymes 41. In addition, Kälsch et al. observed that in population based 
Heinz Nixdorf RECALL Study increasing liver enzymes (transaminases) even within normal ranges 
were significantly associated with metabolic changes, i.e., HbA1c, BMI and Type 2 diabetes 42. These 
observations support the present results of metabolic disturbances associated with FL. Interestingly, 
fatty liver status shared several pathways also associated with atherosclerosis or atherothrombosis 
(CD40/CD40L signaling pathway, Netrin-1 signaling and pathways contributing to thrombosis) i.e., 
another lipid related condition where lipids are accumulated to artery wall. Furthermore, recent 
research results would also suggest to link integrin A4B1 to atherosclerosis, where macrophages 
activate integrin A4B1 by expression of kindlin-3 43 in atherosclerotic plaques 44. These shared 
pathways may form a common link between these two disease states where fatty liver is shown to 
increase the risk of cardiovascular diseases 5. This suggestion is also supported by Baars et al., who 
found that elevated liver parameters are associated with stenosis diameter in acute myocardial 
infarction 45. 
A strength of the present study is that the subjects are based on the well-powered prospective 
randomly selected population based cohort, followed up for over 30 years with long well-known 
history of alcohol use and disease history. This study had large cohort (n = 1,650) and this adds the 
confidence to the present results. In addition, we used strict FDR limit in GSEA results and heavily 
adjusted our analysis with known fatty liver risk factors. The original suggestion was FDR <0.25 but 
we used FDR <0.05 as a limit. The strict FDR limit combined to the large number of subjects and 
adjustment with known risk factors makes the results of this study reliable. 
Limitations of the study include population homogeneity: all subjects are Finnish, ethnically 
homogenous Caucasian people. Because of that these results can be only generalizable in Caucasians. 
We unfortunately had no possibility for validation of the results in other comparable cohort. 
Therefore, we recommend the replication of our results and corresponding analysis for further 
research. In addition, majority of individuals with FL in our population are men. Even though sex has 
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been included in statistical analyses as covariate and sex stratified analyses were performed, possible 
features specific for FL in women could have been missed due to low number of women with FL. 
The results cannot therefore be directly generalized to older populations with equal amounts of 
women and men with FL. 7 The number of subjects in AFL group limited (n=55), which is probably 
insufficient to reveal the alterations in the expression of gene pathways in this subgroup. Subjects 
with FL had more metabolic disorders, which may influence to the present results. 
Furthermore, there is a risk of complications when the liver biopsy is taken and it is therefore 
unacceptable (unethical) to take liver biopsies from healthy asymptomatic individuals on population 
based studies. Analyzing blood samples is much safer and thus makes it possible to have much larger 
cohorts. Thus, we decided to analyze gene expression from blood tissue, which restricts the present 
observations to extrahepatic changes. 
The key concept of analyzing gene sets instead of separate genes is considered as a strength of this 
study. The blood gene pathways reflect real metabolic and systemic functions. We were able to reveal 
much broader biological mechanisms related to the FL using metabolic pathways instead of single 
genes. 
In conclusion, FL was associated with blood gene sets of inflammatory response, immune system 
activation and prothrombotic state. These activated blood pathways may serve as a systemic link 
between FL and the development of cardiovascular diseases.  
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10 TABLES 
10.1 Table 1 
Summary of the 1,650 study participants: classified into normal liver and fatty liver groups of FL, 
NAFL and AFL. Values are mean (SD). 
  NL FL NAFL AFL 
Number of subjects in group 1,334 316 223 55 
Age, years 41.55 (5.07) 43.16 (4.73) 42.91 (4.83) 44.47 (4.32) 
Males (%) 534 (40.0) 221 (69.9) 151 (67.7) 42 (76.4) 
Body mass index, kg/m2 25.60 (4.37) 30.75 (5.43) 30.99 (5.64) 30.01 (5.17) 
Waist to hip ratio  0.88 (0.08) 0.98 (0.07) 0.98 (0.08) 0.99 (0.08) 
Daily smokers (%) 172 (13.5) 48 (16.6) 34 (15.3) 14 (25.5) 
Diabetics (%) 22 (1.7) 41 (13.1) 28 (12.7) 8 (14.5) 
Metabolic syndrome (%) 167 (12.7) 183 (59.0) 130 (59.4) 33 (62.3) 
Systolic BP, mmHg 117.38 (13.60) 128.22 (14.20) 126.89 (13.09) 132.61 (14.82) 
Diastolic BP, mmHg 73.56 (9.86) 82.38 (10.64) 82.01 (10.61) 83.40 (10.89) 
Apolipoprotein B, g/L 1.01 (0.26) 1.23 (0.33) 1.23 (0.33) 1.24 (0.31) 
Triglycerides, mmol/L 1.15 (0.71) 2.04 (1.60) 2.07 (1.73) 1.96 (1.05) 
Insulin, mU/L 8.11 (9.81) 17.70 (20.52) 17.81 (16.78) 14.69 (10.47) 
ALT, U/L 14.40 (7.89) 26.91 (13.60) 26.57 (13.79) 30.16 (13.94) 
AST, U/L 20.57 (5.43) 25.86 (6.99) 25.31 (6.99) 29.35 (7.03) 
GT, U/L 24.90 (15.88) 46.66 (23.90) 45.29 (22.95) 58.03 (24.77) 
CRP, mg/L 1.39 (2.14) 2.53 (3.24) 2.45 (3.09) 2.81 (3.78) 
Alcohol consumption, drinks/day 0.71 (1.01) 1.25 (1.59) 0.65 (0.63) 3.70 (1.95) 
Alcohol consumption, g/day 8.50 (12.16) 15.02 (19.13) 7.78 (7.53) 44.38 (23.42) 
Physical activity index 9.20 (1.83) 8.40 (1.87) 8.50 (1.84) 8.06 (1.99) 
Note: Alcohol consumption was available from 1,536 subjects. Statistics: Mann-Whitney test was 
used for continuous parameters and χ2 test for classified parameters when each fatty liver group was 
compared to controls (NL group). P<0.001 for all other comparisons, except smoking (FL p=0.209, 
NAFL p=0.548 and AFL p=0.022) and alcohol consumption (NAFL p=0.192). Abbreviations: NL, 
normal liver; FL, Fatty liver; NAFL, non-alcoholic fatty liver; AFL, alcoholic fatty liver; ALT, 
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alanine aminotransferase; AST, aspartate aminotransferase; GT, glutamyltransferase; CRP, C-
reactive protein. 
10.2 Table 2 
Gene sets upregulated in subjects with FL compared to NL using GSEA and adjusting for sex, age 
and 20 principal components (Model 1).  
Gene set name SIZE ES NES Nominal P value FDR Q value 
ECM turnover      
  INTEGRIN_A4B1_PATHWAY 25 0.66 2.22 <0.001 0.003 
  INTEGRIN_CELL_SURFACE_INTERACTIONS 47 0.61 2.22 <0.001 0.002 
  ECM_RECEPTOR_INTERACTION 36 0.59 1.98 <0.001 0.031 
  MCALPAIN_PATHWAY 17 0.69 2.02 <0.001 0.029 
Immune response regulation      
  CD40_PATHWAY 25 0.65 2.10 <0.001 0.010 
  LEUKOCYTE_TRANSENDOTHELIAL_MIGRATION 75 0.51 2.04 <0.001 0.025 
  SIGNALLING_TO_ERKS 28 0.57 1.93 <0.001 0.049 
  HIVNEF_PATHWAY 54 0.49 1.93 0.002 0.046 
Thrombosis      
  INTEGRIN_ALPHAIIB_BETA3_SIGNALING 20 0.72 2.16 <0.001 0.004 
  PLATELET_AGGREGATION_PLUG_FORMATION 25 0.75 2.26 <0.001 0.003 
  UPA_UPAR_PATHWAY 23 0.65 2.00 0.004 0.035 
Neural tissue      
  NETRIN1_SIGNALING 20 0.64 2.02 <0.001 0.026 
  AGR_PATHWAY 20 0.66 1.98 <0.001 0.034 
  ALPHA_SYNUCLEIN_PATHWAY 26 0.57 1.89 0.004 0.049 
Gene sets with FDR <0.05, no gene sets were enriched (FDR <0.05) for downregulation in subjects 
with FL. Abbreviations: NL, normal liver; FL, fatty liver; GSEA, gene set enrichment analysis; ES, 
enrichment score; NES, normalized enrichment score; FDR, false discovery rate. 
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10.3 Table 3 
Upregulated gene sets with different adjustment models for covariates. Values are shown as nominal 
p values for each gene set in the specified groups compared to normal liver group (n=1334). 
 FL (n=316) NAFL (n=223) AFL (n=55) 
Gene set name M1 M2 M1 M2 M1 M2 
ECM turnover 
      
  INTEGRIN_A4B1_PATHWAY <0.001 0.013 <0.001 0.012 0.820 NA 
  INTEGRIN_CELL_SURFACE_INTERACTIONS <0.001 0.289 <0.001 0.768 0.025 0.102 
  ECM_RECEPTOR_INTERACTION <0.001 0.370 0.002 NA 0.132 0.674 
  MCALPAIN_PATHWAY <0.001 0.076 0.004 0.089 0.168 0.542 
Immune response regulation 
      
  CD40_PATHWAY <0.001 <0.001 <0.001 <0.001 0.075 0.376 
  LEUKOCYTE_TRANSENDOTHELIAL_MIGRATION <0.001 0.023 0.016 0.092 0.203 0.369 
  SIGNALLING_TO_ERKS <0.001 0.054 0.002 0.082 0.088 0.271 
  HIVNEF_PATHWAY 0.002 0.080 0.004 0.215 0.042 0.191 
Thrombosis 
      
  INTEGRIN_ALPHAIIB_BETA3_SIGNALING <0.001 0.227 0.006 0.926 <0.001 0.119 
  PLATELET_AGGREGATION_PLUG_FORMATION <0.001 0.185 0.004 0.898 <0.001 0.139 
  UPA_UPAR_PATHWAY 0.004 0.107 0.006 0.098 0.017 0.307 
Neural tissue 
      
  NETRIN1_SIGNALING <0.001 0.018 <0.001 0.012 0.202 NA 
  AGR_PATHWAY <0.001 0.110 <0.001 0.133 0.336 NA 
  ALPHA_SYNUCLEIN_PATHWAY 0.004 0.479 <0.001 0.393 0.242 0.959 
 
Statistics: Model 1 (M1) is adjusted for age, sex and 20 principal components; Model 2 (M2) is 
adjusted for age, sex, 20 principal components, body mass index, apolipoprotein B, triglycerides, 
insulin, systolic blood pressure, ALT, alcohol consumption and physical activity index. FL, Fatty 
liver; NAFL, non-alcoholic fatty liver; AFL, alcoholic fatty liver. NA means that the pathway was not 
upregulated in the specific group. 
 
